Current medical imaging · 2026
Clinical Insights and Therapeutic Strategies for Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Case Report with Literature Review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhong Xiaoling, Zeng Guohua, Tang Yinghui, You Shuyuan, Zhan Ke, Chen Yu, Zhang Lixiang
Аннотация
BACKGROUND: Fumarate Hydratase-deficient Renal Cell Carcinoma (FH-d RCC) is a rare autosomal dominant malignancy caused by germline mutations in the fumarate hydratase gene. This aggressive renal cell carcinoma subtype predominantly affects young patients, exhibiting features of type II papillary renal cell carcinoma with early metastatic potential.
CASE PRESENTATION: We present a case of a 38-year-old male diagnosed with FH-d RCC accompanied by retroperitoneal lymph node and vertebral bone metastases. Initial contrast-enhanced computed tomography revealed a 2-cm solid-cystic lesion in the upper pole of the left kidney, retroperitoneal lymphadenopathy, and multiple osteolytic vertebral lesions. The tumor was staged as T1aN1M1. The patient then underwent laparoscopic partial left nephrectomy, para-aortic lymph node dissection, and vertebroplasty. Postoperatively, the patient received cabozantinib, tislelizumab, and denosumab. At the 36-month follow-up, the patient remains progression-free, with the bone metastases having resolved.
CONCLUSION: This case demonstrates the atypical clinical and imaging features, as well as the feasibility of a multidisciplinary comprehensive treatment approach for FH-d RCC, providing valuable insights for the diagnosis and management of this rare subtype of renal cancer.
CASE PRESENTATION: We present a case of a 38-year-old male diagnosed with FH-d RCC accompanied by retroperitoneal lymph node and vertebral bone metastases. Initial contrast-enhanced computed tomography revealed a 2-cm solid-cystic lesion in the upper pole of the left kidney, retroperitoneal lymphadenopathy, and multiple osteolytic vertebral lesions. The tumor was staged as T1aN1M1. The patient then underwent laparoscopic partial left nephrectomy, para-aortic lymph node dissection, and vertebroplasty. Postoperatively, the patient received cabozantinib, tislelizumab, and denosumab. At the 36-month follow-up, the patient remains progression-free, with the bone metastases having resolved.
CONCLUSION: This case demonstrates the atypical clinical and imaging features, as well as the feasibility of a multidisciplinary comprehensive treatment approach for FH-d RCC, providing valuable insights for the diagnosis and management of this rare subtype of renal cancer.